Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs

Acromegaly is a condition most commonly diagnosed in the fifth decade of life and has numerous treatment options. In this regard, Mycapssa(®) is the first FDA-approved oral octreotide capsule for treating acromegaly, combining the efficacy of the somatostatin receptor ligand, octreotide, with the ea...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Charles P., Wagner, Maxwell J., Borne, Grant E., Plaisance, Connor J., Ahmadzadeh, Shahab, Aquino, Alfonso, Shekoohi, Sahar, Kaye, Adam M., Cornett, Elyse M., Kaye, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537411/
https://www.ncbi.nlm.nih.gov/pubmed/37755395
http://dx.doi.org/10.3390/pathophysiology30030029

Ejemplares similares

Ejemplares similares